162 related articles for article (PubMed ID: 35637423)
1. Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.
Peters XQ; Agoni C; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):505-518. PubMed ID: 35637423
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Effects of Chirality of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl) phenyl]imidazolidine-2,4-dione and its Derivatives on the Oncological Target Tankyrase 2. Atomistic Insights.
Quintina Peters X; Poonan P; Salifu Yakubu E; Issa Alahmdi M; Abo-Dya NE; Soliman M
Curr Pharm Biotechnol; 2023 Mar; ():. PubMed ID: 37005548
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Path to Triple Knockout: Investigating the Pan-inhibitory Mechanisms of AKT, CDK9, and TNKS2 by a novel 2-Phenylquinazolinone derivative in Cancer Therapy- An In-Silico Investigation.
Peters XQ; Elamin G; Aljoundi A; Alahmdi MI; Abo-Dya NE; Sidhom PA; Tawfeek AM; Ibrahim MAA; Soremekun O; Soliman MES
Curr Pharm Biotechnol; 2023 Aug; ():. PubMed ID: 37581526
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase.
Eisemann T; Langelier MF; Pascal JM
J Biol Chem; 2019 Oct; 294(40):14574-14590. PubMed ID: 31375564
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of novel biologically active heterocyclic compounds from 2-oxo-2H-benzopyran-6-yl-imidazolidine.
Mulwad VV; Langi BP; Chaskar AC
Acta Pol Pharm; 2011; 68(1):39-47. PubMed ID: 21485700
[TBL] [Abstract][Full Text] [Related]
6. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment.
Morrone S; Cheng Z; Moon RT; Cong F; Xu W
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1500-5. PubMed ID: 22307604
[TBL] [Abstract][Full Text] [Related]
8. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
9. Human Cytomegalovirus Inhibits the PARsylation Activity of Tankyrase--A Potential Strategy for Suppression of the Wnt Pathway.
Roy S; Liu F; Arav-Boger R
Viruses; 2015 Dec; 8(1):. PubMed ID: 26729153
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.
Cheng H; Li X; Wang C; Chen Y; Li S; Tan J; Tan B; He Y
Cancer Lett; 2019 Feb; 443():80-90. PubMed ID: 30472184
[TBL] [Abstract][Full Text] [Related]
11. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
[TBL] [Abstract][Full Text] [Related]
12. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
13. Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/
Yang HY; Shen JX; Wang Y; Liu Y; Shen DY; Quan S
Biomed Res Int; 2019; 2019():2686340. PubMed ID: 30915350
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.
Pu Y; Zhang S; Chang Z; Zhang Y; Wang D; Zhang L; Li Y; Zuo Z
Mol Biosyst; 2017 Jan; 13(2):363-370. PubMed ID: 27995250
[TBL] [Abstract][Full Text] [Related]
15.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
16. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
17. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
18. The ADP-ribose polymerase Tankyrase regulates adult intestinal stem cell proliferation during homeostasis in Drosophila.
Wang Z; Tian A; Benchabane H; Tacchelly-Benites O; Yang E; Nojima H; Ahmed Y
Development; 2016 May; 143(10):1710-20. PubMed ID: 27190037
[TBL] [Abstract][Full Text] [Related]
19. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
[TBL] [Abstract][Full Text] [Related]
20. Graph theoretical analysis, in silico modeling, prediction of toxicity, metabolism and synthesis of novel 2-(methyl/phenyl)-3-(4-(5-substituted-1,3,4-oxadiazol-2-yl) phenyl) quinazolin-4(3H)-ones as NMDA receptor inhibitor.
Saravanan G; Panneerselvam T; Kunjiappan S; Parasuraman P; Alagarsamy V; Udayakumar P; Soundararajan M; Joshi SD; Ramalingam S; Ammunje DN
Drug Dev Res; 2019 May; 80(3):368-385. PubMed ID: 30609096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
